By Pharma Doc : Introduction: Gilead (NASDAQ: GILD ) is an innovative biotech company that ..... antivirals (HIV). Through key acquisitions, Gilead has expanded its pipeline to include Hepatitis ..... easily the biggest drug launch ever. Gilead 's acquision of Calistoga in 2011 for
its nucleotide, ACH-3422. Research suggests that if trials show that this nucleotide works only as well or worse than Gilead 's (NASDAQ: GILD ) Sovaldi or Merck's (NYSE: MRK ) nucleotide it acquired from Idenix (NASDAQ: IDIX ), IDX-21437, then ACH-3422
NEW YORK, Sept 15 (Reuters) - Biotech stocks were tracking for their third straight decline on Monday, weighed down by a drop in Gilead Sciences after the latest developments regarding its hepatitis...
Gilead Sciences (NASDAQ: GILD ) signs non-exclusive license agreements ..... receive a complete technology transfer of Gilead 's manufacturing process to enable ..... prices and pay a royalty on sales to Gilead that will support product registrations
NEW DELHI/MUMBAI, Sept 15 (Reuters) - U.S. drugmaker Gilead Sciences Inc said on Monday it has licensed its hepatitis C drug to seven companies including Cipla Ltd and Ranbaxy Laboratories Ltd to...
* Says licensed Hep C drug Sovaldi to 7 companies including Cipla Ltd, Mylan laboratories, Ranbaxy
inflammatory related diseases. The company is a cohort in a quartet of large, powerful bio-pharmas. The others are Gilead (NASDAQ: GILD ), Regeneron (NASDAQ: REGN ) and Biogen Idec (NASDAQ: BIIB ). Management is deep and well-respected. Chairman / CEO
Emergency Plan for AIDS Relief). The branded Emtricitabine/tenofovir (200 mg/300 mg) product is Gilead Sciences ' (NASDAQ: GILD ) Truvada . Nevirapine (200 mg) tablets are sold under the brand name Viramune by Boehringer Ingelheim
LOS ANGELES, Sept 13 (Reuters) - The next generation version of Gilead Sciences Inc 's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.
LOS ANGELES, Sept 12 (Reuters) - The next generation version of Gilead Sciences Inc 's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.